NRX Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for NRX Pharmaceuticals (NRXP).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$30Upside to Avg. PT+1097.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$50→$51
Oct 1, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$49→$50
Sep 14, 2026	BTIG	Thomas Shrader	Maintained	Buy	$10
Aug 25, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$45
Aug 18, 2026	BTIG	Thomas Shrader	Maintained	Buy	$10
Aug 7, 2026	BTIG	Thomas Shrader	PT Cut	Buy	$25→$10
May 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Apr 27, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$45
Apr 27, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$48→$49
Apr 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Apr 20, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 24, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Mar 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 3, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$40→$45
Feb 18, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Feb 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Jan 15, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25

Analyst Ratings News

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.

Benzinga Newsdesk

NRX Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

NRX Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

People Also Watch

People Also Watch

NRX Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

NRX Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

PROAscendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51

PROAscendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

PROBTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

PROHC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PROBTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10